ACCESS TO THERAPY IN THE MULTICENTER AIDS COHORT STUDY, 1989-1992

被引:56
作者
GRAHAM, NMH
JACOBSON, LP
KUO, V
CHMIEL, JS
MORGENSTERN, H
ZUCCONI, SL
机构
[1] JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205
[2] NORTHWESTERN UNIV,SCH MED,CTR CANC,BIOMETRY SECT,CHICAGO,IL 60208
[3] UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024
[4] UNIV PITTSBURGH,GRAD SCH PUBL HLTH,INST HLTH POLICY,PITTSBURGH,PA 15260
关键词
HIV-1; AIDS; ZIDOVUDINE; DIDANOSINE; DIDEOXYCYTIDINE; HEALTH CARE UTILIZATION;
D O I
10.1016/0895-4356(94)90115-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95% CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).
引用
收藏
页码:1003 / 1012
页数:10
相关论文
共 30 条
  • [1] BONUCK A, 1992, 120TH AM PUBL HLTH A
  • [2] RECONSTRUCTION AND FUTURE-TRENDS OF THE AIDS EPIDEMIC IN THE UNITED-STATES
    BROOKMEYER, R
    [J]. SCIENCE, 1991, 253 (5015) : 37 - 42
  • [3] SAFETY AND EFFICACY OF SULFAMETHOXAZOLE AND TRIMETHOPRIM CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN AIDS
    FISCHL, MA
    DICKINSON, GM
    LAVOIE, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (08): : 1185 - 1189
  • [4] THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISCHL, MA
    RICHMAN, DD
    GRIECO, MH
    GOTTLIEB, MS
    VOLBERDING, PA
    LASKIN, OL
    LEEDOM, JM
    GROOPMAN, JE
    MILDVAN, D
    SCHOOLEY, RT
    JACKSON, GG
    DURACK, DT
    KING, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) : 185 - 191
  • [5] GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296
  • [6] THE EFFECTS ON SURVIVAL OF EARLY TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    GRAHAM, NMH
    ZEGER, SL
    PARK, LP
    VERMUND, SH
    DETELS, R
    RINALDO, CR
    PHAIR, JP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) : 1037 - 1042
  • [7] EFFECT OF ZIDOVUDINE AND PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS ON PROGRESSION OF HIV-1 INFECTION TO AIDS
    GRAHAM, NMH
    ZEGER, SL
    PARK, LP
    PHAIR, JP
    DETELS, R
    VERMUND, SH
    HO, MT
    SAAH, AJ
    [J]. LANCET, 1991, 338 (8762) : 265 - 269
  • [8] GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267
  • [9] A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021
    HARDY, WD
    FEINBERG, J
    FINKELSTEIN, DM
    POWER, ME
    HE, W
    KACZKA, C
    FRAME, PT
    HOLMES, M
    WASKIN, H
    FASS, RJ
    POWDERLY, WG
    STEIGBIGEL, RT
    ZUGER, A
    HOLZMAN, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) : 1842 - 1848
  • [10] HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356